Non-small-cell lung cancer associated with excessive eosinophilia and secretion of interleukin-5 as a paneoplastic syndrome

American Journal of Hematology

Volumn 82, Issue 3, 2007, Pages 234-237

  Pandit, Renu ^a,b   Scholnik, Aaron ^a   Wulfekuhler, Louis ^a   Dimitrov, Nikolay ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Interleukin 5; Paraneoplastic syndrome; Tumor associated eosinophilia

Indexed keywords

INTERLEUKIN 5;

AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; EOSINOPHIL COUNT; EOSINOPHILIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; MALE; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; EOSINOPHILIA; EOSINOPHILS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-5; LEUKOCYTE COUNT; LUNG NEOPLASMS; MALE; PARANEOPLASTIC SYNDROMES;

EID: 33847673670     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20789     Document Type: Article

References (15)

1. Samoszuk M. Eosinophils and human cancer. Histol Histopathol 1997;12:807-812.
2. Stefanini M, Claustro JC, Motos RA, Bendigo LL. Blood and bone marrow eosinophilia in malignant tumors. Cancer 1991;68:543-548.
3. Slungaard A, Ascensao J, Zanjani E, Jacob HS. Pulmonary carcinoma with eosinophilia. N Engl J Med 1983;309:778-781.
4. Sanderson CJ. Interleukin-5. In: Thompson A, editor. The Cytokine Handbook. London: Academic Press; 1998. pp 175-197.
5. Dent LA, Strath M, Mellor AL, Sanderson CJ. Eosinophilia in transgenic mice expressing interleukin-5. J Exp Med 1990;172:1425-1431.
6. Vaux DL, Lalor PA, Cory S, Johnson GR. In vivo expression of interleukin-5 induces an eosinophilia and expanded Ly-1B lineage populations. Int Immunol 1990;2:965-971.
7. Hamid Q, Azzawi M, Ying S, Moqbel R, Wardlaw AJ, Corrigan CJ, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991;87:1541-1546.
8. Limaye AP, Abrams JS, Silver JE, Awadzi K, Francis HF, Ottesen EA, et al. Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis. J Clin Invest 1991;88:1418-1421.
9. Macdonald D, Gordon AA, Kajitani H, Enokihara H, Barrett AJ. Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production. Br J Haematol 1990;76:168-173.
10. Yamaguchi Y, Hayashi Y, Sugama Y, Miura Y, Kasahara T, Kitamura S, et al. Highly purified murine interleukin-5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med 1988;167:1737-1742.
11. Rivoltini L, Viggiano V, Spinazze S, Santoro A, Colombo MP, Takatsu R, et al. In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin-2. Role of interleukin-5. Int J Cancer 1993;54:8-15.
12. Rothenberg ME. Eosinophilia. N Engl J Med 1998;338:1592-1600.
13. Isaacson NH, Rappoport P. Eosinophilia in malignant tumors: Its significance. Ann Intern Med 1946;25:893-902.
14. Balian A, Bonta E, Neveau S, Foussat A, Bouchet-Delbos L, Berrrebi D, et al. Intratumoral production of interleukin-5 leading to paraneoplastic peripheral eosinophilia in hepatocellular carcinoma. J Hepatol 2001;34:355-356.
15. Fridlender ZG, Simon HU, Shalit M. Metastatic carcinoma presenting with concomitant eosinophilia and thromboembolism. Am J Med Sci 2003;326:98-101.